All In MedTech

FDA Clearance Tracker · P060005

IMMULITE / IMMULITE 1000 AND IMMULITE 2000 FREE PSA ASSAYS

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: May 11, 2007 (this decision)Source: openFDAMethods & limitations

PMA

Decided

May 11, 2007

Approved

Time to decision

451 days

Received Feb 14, 2006. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P060005
Device name
IMMULITE / IMMULITE 1000 AND IMMULITE 2000 FREE PSA ASSAYS
Applicant location
Gwynedd Ll55
Received
Feb 14, 2006
Decided
May 11, 2007
Decision
Approved
Supplements
21 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MTG

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE IMMULITE / IMMULITE 1000 AND IMMULITE 2000 FREE PSA ASSAY. THESE DEVICES ARE INDICATED FOR: THE IMMULITE / IMMULITE 1000 FREE PSA ASSAY IS INDICATED FOR IN VITRO DIAGNOSTIC USE WITH THE IMMULITE / IMMULITE 1000 ANALYZER FOR THE QUANTITATIVE MEASUREMENT OF FREE PROSTATE-SPECIFIC ANTIGEN (PSA) NOT BOUND TO ALPHA 1-ANTICHYMOTRYPSIN OR OTHER BINDING PROTEINS (UNCOMPLEXED) IN HUMAN SERUM (INCLUDING SERUM COLLECTED IN SERUM GLASS, SERUM PLASTIC AN SERUM GEL SEPARATOR TUBES). MEASUREMENT OF FREE PSA IS USED IN CONJUNCTION WITH IMMULITE / IMMULITE 1000 TOTAL PSA TO DETERMINE A RATIO OF FREE PSA TO TOTAL PSA (PERCENT FREE PSA). THE PERCENT FREE PSA IS USED AS AN AID IN DISCRIMINATING PROSTATE CANCER FROM BENIGN DISEASE IN MEN 50 YEARS OR OLDER WITH IMMULITE / IMMULITE 1000 TOTAL PSA VALUES BETWEEN 4 AND 10 NG/ML AND DIGITAL RECTAL EXAM (DRE) FINDINGS NOT SUSPICIOUS OF CANCER. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF PROSTATE CANCER. THE IMMULITE 2000 FREE PSA ASSAY IS INDICATED FOR IN VITRO DIAGNOSTIC USE WITH THE IMMULITE 2000 ANALYZER FOR THE QUANTITATIVE MEASUREMENT OF FREE PROSTATE-SPECIFIC ANTIGEN (PSA) NOT BOUND TO ALPHA 1-ANTICHYMOTRYPSIN OR OTHER BINDING PROTEINS (UNCOMPLEXED) IN HUMAN SERUM (INCLUDING SERUM COLLECTED IN SERUM GLASS, SERUM PLASTIC AN SERUM GEL SEPARATOR TUBES). MEASUREMENT OF FREE PSA IS USED IN CONJUNCTION WITH IMMULITE 2000 TOTAL PSA TO DETERMINE A RATIO OF FREE PSA TO TOTAL PSA (PERCENT FREE PSA). THE PERCENT FREE PSA IS USED AS AN AID IN DISCRIMINATING PROSTATE CANCER FROM BENIGN DISEASE IN MEN 50 YEARS OR OLDER WITH IMMULITE 2000 TOTAL PSA VALUES BETWEEN 4 AND 10 NG/ML AND DIGITAL RECTAL EXAM (DRE) FINDINGS NOT SUSPICIOUS OF CANCER. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF PROSTATE CANCER.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MTG. The earliest in FDA's data is P950021, decided Dec 22, 1995.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Siemens Medical Solutions Diagnostics Limited

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.